BioAtla Earnings Estimates, EPS & Revenue | NASDAQ:BCAB

Comments

BioAtla Inc Earnings Estimates

BCABNASDAQ

Trade with Public

$4.46

-0.06-1.33%

At close: Apr 10, 5:00 PM EST

$4.56

0.12.24%

After Hours: Apr 10, 7:37 PM EST

Stock Split: BioAtla Inc is expected to split Monday, April 6, 2026 with a ratio of 1:50

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

BioAtla Earnings Estimates, EPS & Revenue | NASDAQ:BCAB

BioAtla (BCAB) is scheduled to report Q1 earnings on May 5, 2026. Analysts estimate EPS of $-0.37 and quarterly revenue of N/A.

In the most recent quarter (Q4), BioAtla reported EPS of $-0.16, beating estimates of $-0.36 by 0.56%. Revenue came in at $2.00M, exceeding the estimate of $700.00K by 1.86%.

BioAtla has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, BioAtla has averaged an EPS surprise of 0.22% and a revenue surprise of 1.86%.

Earnings Date

May 5

EPS Estimate

$-0.370

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

$2.00M

BioAtla Earnings History

Analyze the earnings history of BioAtla using advanced sorting and filters.

Loading calendar...

BioAtla (BCAB) Earnings Per Share

The chart below shows BioAtla's reported EPS compared to analyst estimates over recent quarters.

BioAtla (BCAB) Revenue

The chart below shows BioAtla's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is BioAtla (NASDAQ:BCAB) reporting earnings?

BioAtla (BCAB) is scheduled to report earnings on May 5, 2026. The last reported earnings were for reported on March 31, 2026 for Q4.

What were the latest earnings per share (EPS) for BioAtla (NASDAQ:BCAB)?

The Actual EPS was $-0.16, which beat the estimate of $-0.36.

What were BioAtla’s (NASDAQ:BCAB) revenues?

The Actual Revenue was $2.00M, which beat the estimate of $700.00K.

People Also Watch

Immuron Ltd

NASDAQ:IMRN

$0.79

Acurx Pharmaceuticals Inc

NASDAQ:ACXP

$2.76

5.90%

Quoin Pharmaceuticals Ltd

Can Fite Biopharma Ltd

AMEX:CANF

$2.92

Bolt Biotherapeutics Inc

NASDAQ:BOLT

$4.96

1.02%

AlphaTON Capital Corp

NASDAQ:ATON

$0.30

-3.07%

AIxCrypto Holdings Inc

NASDAQ:AIXC

$1.36

BioAtla Earnings Estimates, EPS & Revenue | NASDAQ:BCAB

BioAtla (BCAB) is scheduled to report Q1 earnings on May 5, 2026. Analysts estimate EPS of $-0.37 and quarterly revenue of N/A.

In the most recent quarter (Q4), BioAtla reported EPS of $-0.16, beating estimates of $-0.36 by 0.56%. Revenue came in at $2.00M, exceeding the estimate of $700.00K by 1.86%.

BioAtla has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, BioAtla has averaged an EPS surprise of 0.22% and a revenue surprise of 1.86%.

Earnings Date

May 5

EPS Estimate

$-0.370

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

$2.00M